Clear the zombie cells left behind by chemotherapy and radiotherapy

Therapy-induced senescence produces a secretory phenotype that promotes proliferation, angiogenesis and immune suppression, and senescent tumour cells can re-enter the cell cycle. Senolytics such as navitoclax-class BCL-2 family inhibitors and dasatinib-quercetin combinations clear these cells in models, and a one-two sequence of pro-senescence therapy followed by a senolytic has shown benefit preclinically.